The fast-tracking of mRNA-based vaccines in the face of a real-life global pandemic has been a revelation and one which has opened up possibilities for harnessing mRNA products against a wide range of viruses. The race is now on to develop the next generation of mRNA therapeutics using machine learning and AI techniques for target identification, and the integration of full digitization tools into user-friendly platforms could present significant advantages.
Stepping into this arena is US-based biotechnology company Translate Bio, headquartered in Lexington, Massachusetts, specializing in mRNA products and co-developing vaccines with collaborator Sanofi Pasteur. Its data science manager, Emma McIntosh, has begun organizing the company’s data flows and implementing electronic lab notebooks that bring a whole host of efficiency benefits and help with regulatory compliance.
Learn how Translate Bio (now acquired by Sanofi) uses eLabJournal to speed the development of mRNA-based vaccines.
> Read the full article on SelectScience
What stuck out about the eLabJournal software is that it was so easy for people to lift their process from saving their information to a shared drive to saving it all into an electronic lab notebook.
Learn how the Fox Lab at UNMC moved away from their paper, digital hybrid approach for a more optimized research process.Read more
Learn how NEOsphere Biotechnologies uses eLabJournal to streamline their experimentation process.Read more
Learn how Boston University implemented an in-house COVID-19 testing lab with the adoption of eLabJournal and utilization of eLab API.Read more
Schedule a Personal Demo for friendly expert guidance and a free lab workflow assessment.